Related Experiment Video

Updated: May 19, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Activity and complexes of mTOR in diffuse large B-cell lymphomas--a tissue microarray study

Anna Sebestyén1, Tamás B Sticz, Agnes Márk

  • 11st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary. anna@korb1.sote.hu

Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|August 18, 2012
PubMed

Insights

Targeting the mammalian target of rapamycin (mTOR) pathway shows promise for treating diffuse large B-cell lymphoma. mTOR activity is prevalent in non-germinal center subtypes, suggesting potential therapeutic benefits but requiring careful patient selection for mTOR inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous malignancy with variable treatment responses.
  • Targeting the mammalian target of rapamycin (mTOR) pathway is an emerging therapeutic strategy for lymphomas.
  • Limited data exists on mTOR activity and its complexes in DLBCL.

Purpose of the Study:

  • To investigate mTOR activity and protein expression in DLBCL subtypes.
  • To correlate mTOR activity with clinical outcomes and patient survival.
  • To assess the potential of mTOR inhibitors in DLBCL treatment.

Main Methods:

  • Tissue microarrays from 68 DLBCL biopsies were analyzed.
  • Over 700 immunohistochemical stainings assessed mTOR signaling proteins and phosphoproteins.
  • Lymphoma classification markers were used to differentiate subtypes.

Main Results:

  • Germinal center-derived DLBCL showed minimal mTOR activity.
  • Approximately 80% of non-germinal center DLBCL cases exhibited mTOR activity.
  • Rictor overexpression, associated with mTOR activity, correlated with significantly worse patient survival.

Conclusions:

  • mTOR activity is a hallmark of most non-germinal center DLBCLs, indicating potential sensitivity to mTOR inhibitors.
  • Rictor overexpression in conjunction with mTOR activity predicts poor prognosis in DLBCL patients.
  • mTOR inhibitors may offer a valuable addition to standard DLBCL therapy, necessitating careful patient and inhibitor selection.

More Related Videos

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

A Next-generation Tissue Microarray (ngTMA) Protocol for Biomarker Studies09:32

A Next-generation Tissue Microarray (ngTMA) Protocol for Biomarker Studies

Published on: September 23, 2014

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...